FDA approves NRx preservative-free ketamine formulation

NRx Pharmaceuticals received FDA approval for a ketamine drug, according to Investing.com. Pluang identified the product as a preservative-free ketamine formulation and reported that the approval came ahead of the November 10, 2026 deadline.

Reported formulation details

According to Pluang, the approved ketamine product contains no benzethonium chloride. Pluang described benzethonium chloride as a toxic preservative that is banned by the FDA.

Pluang reported that the formulation is manufactured in the U.S. using modern technology. The publisher said the approval addresses ketamine shortages and supports reshoring sterile injectable drug production to the U.S.

Investing.com separately reported that NRx Pharmaceuticals received FDA approval for a ketamine drug. The supplied reports identify the company and the FDA action, while Pluang provides the additional description of the formulation as preservative-free.

Hospital supply context

Pluang reported that NRx plans to supply American hospitals with the preservative-free ketamine option. According to the publisher, ketamine is primarily used for anesthesia and pain control.

For pharmaceutical and biotech sales professionals working with hospital and health-system stakeholders, the reported event concerns an FDA-approved ketamine formulation that Pluang says does not contain benzethonium chloride. The report also places the product in the context of American hospital supply and sterile injectable drug production in the U.S.

The supplied evidence does not provide additional FDA labeling details, distribution timing, product availability information, or clinical-use specifications beyond the anesthesia and pain-control context reported by Pluang.

What the supplied reports establish

• Investing.com reported FDA approval for an NRx Pharmaceuticals ketamine drug.
• Pluang reported that the approved formulation is preservative-free.
• Pluang reported that the product contains no benzethonium chloride.
• Pluang reported that NRx plans to supply American hospitals.
• Pluang reported that the product is manufactured in the U.S.

The approval is the central development reported by both publishers. Pluang’s account adds the product and supply context, including the stated focus on a preservative-free formulation for American hospitals.